RNA sequencing supports distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris nobilis) in HT-29 cells by Rodd, Annabelle L. et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
RNA sequencing supports distinct reactive oxygen species-mediated 
pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris 
nobilis) in HT-29 cells  
Citation:  
Rodd, Annabelle L., Ververis, Katherine, Sayakkarage, Dheeshana, Khan, Abdul W., Rafehi, 
Haloom, Ziemann, Mark, Loveridge, Shanon J., Lazarus, Ross, Kerr, Caroline, Lockett, Trevor, 
El-Osta, Assam, Karagiannis, Tom C. and Bennett, Louise E. 2015, RNA sequencing supports 
distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass 
fractions of Bay leaf (Lauris nobilis) in HT-29 cells, Food & function, vol. 6, no. 8, pp. 2507-
2524. 
DOI: http://www.dx.doi.org/10.1039/c5fo00467e 
 
 
 
© 2015, The Royal Society of Chemistry 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Non-
Commercial Licence 
 
 
 
 
 
Downloaded from DRO: 
http://hdl.handle.net/10536/DRO/DU:30112914 
Food &
Function
PAPER
Cite this: Food Funct., 2015, 6, 2507
Received 28th April 2015,
Accepted 6th June 2015
DOI: 10.1039/c5fo00467e
www.rsc.org/foodfunction
RNA sequencing supports distinct reactive oxygen
species-mediated pathways of apoptosis by high
and low size mass fractions of Bay leaf (Lauris
nobilis) in HT-29 cells
Annabelle L. Rodd,a,b Katherine Ververis,a,b Dheeshana Sayakkarage,a
Abdul W. Khan,c Haloom Rafehi,a,b,c Mark Ziemann,c Shanon J. Loveridge,a
Ross Lazarus,d Caroline Kerr,e Trevor Lockett,e Assam El-Osta,b,c,f,g
Tom C. Karagiannis*a,b and Louise E. Bennett*h
Anti-proliferative and pro-apoptotic eﬀects of Bay leaf (Laurus nobilis) in mammalian cancer and HT-29
adenocarcinoma cells have been previously attributed to eﬀects of polyphenolic and essential oil chemi-
cal species. Recently, we demonstrated diﬀerentiated growth-regulating eﬀects of high (HFBL) versus low
molecular mass (LFBL) aqueous fractions of bay leaf and now conﬁrm by comparative eﬀects on gene
expression, that HFBL and LFBL suppress HT-29 growth by distinct mechanisms. Induction of intra-
cellular lesions including DNA strand breakage by extra-cellular HFBL, invoked the hypothesis that iron-
mediated reactive oxygen species with capacity to penetrate cell membrane, were responsible for HFBL-
mediated eﬀects, supported by equivalent eﬀects of HFBL in combination with γ radiation. Activities of
HFBL and LFBL were interpreted to reﬂect diﬀerentiated responses to iron-mediated reactive oxygen
species (ROS), occurring either outside or inside cells. In the presence of LFBL, apoptotic death was rela-
tively delayed compared with HFBL. ROS production by LFBL mediated p53-dependent apoptosis and
recovery was suppressed by promoting G1/S phase arrest and failure of cellular tight junctions. In com-
parison, intra-cellular anti-oxidant protection exerted by LFBL was absent for extra-cellular HFBL (likely
polysaccharide-rich), which potentiated more rapid apoptosis by producing DNA double strand breaks.
Diﬀerentiated eﬀects on expression of genes regulating ROS defense and chromatic condensation by
LFBL versus HFBL, were observed. The results support ferrous iron in cell culture systems and potentially
in vivo, can invoke diﬀerent extra-cellular versus intra-cellular ROS-mediated chemistries, that may be
regulated by exogenous, including dietary species.
Introduction
Colorectal cancer (CRC) is the third most prevalent cancer
worldwide, representing 10% of all cancers in 2008 and
aﬀecting 1.24 million people.1 CRC is the third leading cause
of cancer-related deaths in industrialized cities2 and the inci-
dence of CRC is increasing in countries where Western dietary
and lifestyle practices are increasing.
Around one third of the variation in CRC sucsceptibility is
attributable to heritable genetic variants. While Mendelian
syndromes that are associated with a high risk of developing
CRC for carriers, notably Lynch Syndrome and Familial
Adenomatous Polyposis, account for around 5% of the
total CRC burden, modern genomics has identified a
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further 30 or more low penetrance predisposing variants.3
Colorectal carcinogenesis is widely accepted to be a sequen-
tial and multi-step process involving accumulation of
mutations aﬀecting oncogenes, tumor-suppressor and DNA-
repair genes that control cell proliferation, cell survival and
oncogenesis.2
Low levels of physical activity, and some dietary practices
such as high red meat consumption, low fruit and vegetable
intake and deficiency of some micro-nutrients have been
associated with increased risk of CRC.4 Alternately, pre-clinical
studies have demonstrated the potential of extracts from
dietary plant including carotenoids,5 cruciferous vegetables
rich in glucosinolates6 and isothiocyanates7 and specific phyto-
chemicals such as curcumin8 and resveratrol9 to be protective
against CRC.
The HT-29 human colonic adenocarcinoma cell line has
been used as a model of cellular growth processes underlying
CRC and a screening tool for investigating eﬀectiveness of
chemopreventative factors.10 More recently, eﬀects of interven-
tions have also been studied by diﬀerential gene regulation
using RNA sequencing methodologies,11 which has extended
the understanding of important growth-regulating genes
beyond the previously narrow foci of mucin12 and heat-shock13
genes. Recent gene profiling studies have shown that the flavo-
noid apigenin stimulated 2–4-fold upregulation of caspase-3
and caspase-8 mRNA while down-regulating rapamycin and
cyclin D1 to 0.4 and 0.2-times the level prior to flavonoid treat-
ment, respectively.11 In addition, diallyl disulfide from garlic,
exhibiting dose and time-dependent growth inhibition of
HT-29 cells, was shown to alter the level of expression of
49 genes involved in controlling transduction, cell prolifer-
ation, cell growth, apoptosis and the protein composition and
structure of the extracellular matrix.14 Apple polyphenolics
that inhibited HT-29 growth have also been shown to modulate
expression of genes involved with xenobiotic metabolism.15 All
of these reported eﬀects of dietary factors on HT-29 cell gene
expression were substantiated by correlation with transcrip-
tional activity.
More recent gene expression studies support the numer-
ous in vitro studies demonstrating anti-proliferative and pro-
apoptotic eﬀects of a range of plant and fungal extracts on
HT-29 cells. In these studies, bioactivity was associated with
diﬀerent chemical classes mostly extracted using organic sol-
vents including: acid methanol extracts from bay leaf and
other Australian native herbs;16 Bowman-Birk protease inhibi-
tor from pea;17 ethanol extract of Phellinus linteus fungus
growing on ginseng;18 butanol extract of Cordyceps militaris
fungus growing on soybean;19 diallyl sulphide from garlic;14
polysaccharide from the fungus, Pleurotus ostreatus;20 poly-
phenolic-rich raspberry extract;21 maslinic and oleanolic
acids (pentacyclic triterpenes) from olives;22 sulforaphane
(isothiocyanate) from broccoli23 and epigallocatechin gallate
from green tea.24 By using solvent-based extraction methods,
these studies have all either intentionally or inadvertently
focused on hydrophobic metabolites including polyphenolics
and essential oils. In all cases, both anti-proliferative and
apoptotic eﬀects measured by cell cycle analysis or caspase-
specific pathways were reported. Extracts of bay leaf are also
reported to regulate growth in human melanoma, kidney,
prostate and breast cancer cell lines.25 We have recently
described divergent extents of anti-proliferation and apop-
tosis associated with higher molecular mass versus lower
mass (polyphenolic, essential oil-rich) fractions of bay leaf
extract on HT-29 cells.26
The aim of this study was to extend our previous studies by
conducting RNA sequencing of HT-29 cells following exposure
to unfractionated (UFBL), low (LFBL) and high (HFBL) mole-
cular mass fractions of bay leaf. The hypothesis that LFBL and
HFBL diﬀerentially interacts with reactive oxygen species (ROS)
was explored by comparing eﬀects of bay leaf fractions in the
presence of Fe-mediated ROS production in cell culture or by
γ radiation-mediated ROS production. The results confirm
previous functional diﬀerences and extend our previous
understanding, suggesting that LFBL and HFBL mediate
diﬀerentiated rates of apoptosis involving reactive oxygen
species (ROS), eliciting diﬀerent pathways of toxicity and cellu-
lar defense and repair responses.
Results
Diﬀerentiated anti-proliferative and apoptotic eﬀects of HFBL
and LFBL on HT-29 cells
LFBL and HFBL were previously shown to exhibit divergent
eﬀects on inhibiting proliferation and promoting apoptosis,
respectively, of HT-29 cells in vitro. The low and high mass
bay leaf fractions were compositionally distinct with expected
enrichment of polyphenolics and essential oils in the low
mass fraction and of polysaccharides and proteins in the
high mass fraction. We have now sought to substantiate these
eﬀects at the gene expression level. The eﬀects of UFBL,
HFBL and LFBL samples on cell viability and induction of
caspase 3/7 activity in HT-29 cells indicated that the LFBL
fraction was responsible for a dose-dependent decrease in
cell viability and proliferation, with more prominent eﬀects
seen at 48 versus 24 hours incubation (Fig. 1). The EC50
values were calculated to be 30, 10 and 61.5 mg mL−1 for
UFBL, LFBL and HFBL, respectively (Fig. 1D). Conversely,
although caspase activity data indicated both HFBL and LFBL
induced a significant increase in apoptosis, the HFBL
induced a greater response in caspase 3/7 activity compared
to LFBL and UFBL (Fig. 1C), as reported previously.26 The
eﬀects of all bay leaf samples produced significant shifts in
the cell cycle with an increase of the proportion of cells in the
S phase and sub-G1 phase and decreases in the proportion of
cells in G1 and G2 phase, after 24 hours. Compared with the
proportion of sub-G1 untreated cells (0.65%), HFBL treatment
significantly increased the sub-G1 proportion to 60.5%
(Table 1). Cell cycle analysis indicated that observed changes
were similar for UFBL and LFBL treatments at either 24 or
48 h with relatively faster eﬀects of HFBL on sub-G1 phase
(Fig. 2).
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HFBL but not LFBL induces DNA-double strand breaks
The comparative eﬃcacy of the UFBL, HFBL and LFBL on the
induction of DNA damage in HT-29 cells was measured using
γH2AX, a marker for double-strand breaks (Fig. 3). Compared
with non-significant production by UFBL and LFBL, induction
of γH2AX foci per cell were significant for HFBL (Fig. 3A and
3B). HFBL-mediated γH2AX lesions, but not LFBL-mediated,
increased as a function of time, and time-dependent pro-
duction of γH2AX foci per cell were amplified by ionizing radi-
ation (Fig. 3C and 3D). Treatment of HT-29 cells with HFBL
but not LFBL, produced significant DNA damage with or
without γ-radiation, suggesting that either γ-radiation-indepen-
dent or γ-radiation-dependent DNA double-strand breaks
mediated by HFBL were not repairable and could account for
the pathway of cell apoptosis mediated by HFBL. These results
also infer potentiation of γ-radiation-induced ROS free radical-
mediated oxidative damage by HFBL, but not LFBL.
mRNA-sequencing and pathway analysis
Global eﬀects of UFBL, HFBL and LFBL on gene expression
in HT-29 cells are shown in Fig. 4 and 5. Histograms of fold-
change distribution (Fig. 4) demonstrated that treatment
with all bay leaf samples primarily caused up-regulation of
gene expression, with values mainly lying between 0 and
5. Furthermore, Venn diagram representation of up-regulated
genes showed there was significant overlap between the
genes up-regulated by all three samples of bay leaf, with
approximately 50% of total up-regulated genes common
across all bay leaf samples (Fig. 5A). These up-regulated
genes were found to be mainly involved in cytoskeleton
Fig. 1 The eﬀects of unfractionated (UFBL), high (HFBL) and low (LFBL) molecular weight fractions of bay leaf on HT-29 cell viability and apoptosis
after treatment for 24 or 48 hours. Treatment with LFBL for 24 (A) and 48 (B) hours induces the greatest dose-dependent decrease in the cell viability
of HT-29 cells. (C) HFBL and LFBL induce apoptosis in HT-29 cells after 48 hours, with HFBL exerting higher apoptotic activity than LFBL. (D) EC50
values of the cell viability for respective bay leaf samples. Shown is a representative experiment performed in triplicate, two independent experi-
ments performed in total. Two-way ANOVA with Bonferroni post-tests were performed comparing each treatment to untreated cells, *P < 0.05, **P
< 0.01, ***P < 0.001.
Table 1 Percentage of HT-29 cells at each stage of cell cycle following treatment with bay leaf fractions
Treatment
Incubation
time (h) Sub-G1 G1 S G2/M
Untreated 0 1.5 ± 1.2 74.0 ± 0.8 10.9 ± 1.9 13.6 ± 1.5
UFBL-20 mg ml−1 24 13.3 ± 0.4 56.8 ± 2.6 4.6 ± 1.8 25.3 ± 4.8
UFBL-20 mg ml−1 48 47.4 ± 14.3 34.5 ± 4.0 0.4 ± 0.3 17.7 ± 10.0
HFBL-10 mg ml−1 24 49.3 ± 8.7 36.5 ± 3.9 1.7 ± 0.8 12.4 ± 3.9
HFBL-10 mg ml−1 48 73.6 ± 11.0 20.0 ± 3.9 0.1 ± 0.1 6.3 ± 7.0
LFBL-10 mg ml−1 24 11.6 ± 1.2 59.0 ± 3.0 8.9 ± 0.9 20.5 ± 5.0
LFBL-10 mg ml−1 48 62.5 ± 8.6 26.7 ± 7.4 0.3 ± 0.3 10.5 ± 0.9
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remodeling, cell cycle disruption, and induction of apoptotic
pathways. LFBL treatment induced the majority of genes to
be up-regulated, followed by the UFBL, and then HFBL. In
contrast, however, a smaller percentage (∼17%) of the down-
regulated genes was common across bay leaf samples
(Fig. 5B). All three samples induced similar numbers of
genes with decreased expression with HFBL > LFBL > UFBL.
While a large proportion of genes were similarly aﬀected by
all three bay leaf samples, the genes that were diﬀerentially
expressed highlight diﬀerent biological pathways aﬀected by
respective fractions. Specific genes with altered expression
were grouped by either cell cycle and apoptosis (Table 2),
those regulating cell junctions and motility (Table 3) and
defense against oxidative stress (Table 4).
Expression of the tumor suppressor p53 was up-regulated
post-treatment by all bay leaf samples, particularly LFBL. P53
activates both the cyclin-dependent kinase (CDK) inhibitors:
p21 (up-regulated expression specifically by LFBL) and p27,
resulting in their increased expression. These genes then
inhibit the expression of CDK2. Moreover, treatment with
LFBL resulted in a decrease in expression of both cyclin A and
cyclin E. A decrease in expression of cyclin A/CDK2 and cyclin
E/CDK complexes aﬀected transition through the S and G1
phases respectively, possibly inducing cell cycle arrest during
the G1/S transition, and subsequently leading to a reduction in
cell proliferation (Fig. 6).
Treatment of HT-29 cells with bay leaf samples also
resulted in distinct changes in expression of multiple genes
involved in apoptosis (Table 2). The intrinsic pathway of cell
death is expected to initiate release of a number of proteins,
including cytochrome c from the inter-membrane space of the
mitochondria into the cytoplasm. It is understood that the
release of such proteins is a result of increased Bim expression
(all three extracts, particularly LFBL, increase its expression),
which directly mediates Bak and Bax (also increased
expression post-treatment with bay leaf ), leading to the cyto-
chrome c release. Cytochrome c then binds to apaf-1 protein,
in turn causing its activation. Apaf-1 subsequently binds ATP/
dATP forming the apoptosome and mediating activation of
caspase 9. This initiates the caspase cascade, leading to the
activation of subsequent caspases, including caspase-3 and
caspase-7, both which are up-regulated following treatment
with bay leaf. Caspase 9 inhibits the expression of PTEN,
which subsequently activates p53 thereby increasing its
expression. Bax plays a pivotal role in inducing apoptosis by
controlling the release of the IAP-binding mitochondrial
protein, Smac/Diablo from the mitochondria. Smac/Diablo
binds to the IAP protein, survivin, subsequently inhibiting it.
Thus, post treatment with bay leaf samples, a decrease in
expression of this protein is observed. Survivin blocks release
of cytochrome c, hence a decrease of survivin leads to
increased expression of cytochrome c, an observation seen fol-
lowing bay leaf treatment. P53 is also involved in initiation of
apoptosis, activating E2F1, which then activates Apaf-1, even-
tually resulting in initiation of the caspase cascade. Further,
p53 is responsible for the activation of both OSGIN1 and
DUSP5, two proteins that have previously been implicated in
malignant cell death. HFBL bay leaf caused a decrease in
expression of DNA repair proteins: Rad51 and Proliferating
Cell Nuclear Antigen (PCNA), both of which are mediated by
Brca1 protein, which also displays elevated expression by bay
leaf treatment (Fig. 6).
Fig. 2 Cell cycle analysis by FACS of HT-29 cells treated with 20 mg
mL−1 UFBL extract and 10 mg mL−1 of HFBL and LFBL fractions for 24
and 48 hours. Gatings from left show proportions of sub-G1, G0/G1, S,
G2/M phase cells, respectively. Treatment with UFBL, HFBL and LFBL
fractions produce a shift to sub-G1 phase comprising both apoptotic
and necrotic cells. Shown are representative data from a single experi-
ment performed in duplicates.
Paper Food & Function
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Fig. 3 HFBL bayleaf fractions augment DNA double-strand breaks represented by γH2AX foci in human colon carcinoma HT-29 cells. (A) Repre-
sentative photomicrographs of cells treated with 20 mg mL−1 UFBL, 10 mg mL−1 HFBL and 10 mg mL−1 LFBL samples for 48 hours prior to γH2AX
staining. Merged image: nucleus stained with TO-PRO3 (blue), γH2AX foci (green). (B) HFBL signiﬁcantly induced formation of γH2AX foci in HT-29.
Images were analysed for the number of γH2AX foci per cell by image analysis and total ﬂuorescence intensity of the γH2AX staining. Shown are the
mean ± SD from two independent experiments each performed in duplicate. (C) Representative photomicrographs of cells treated with or without
4 Gy (137Cs) of γ-radiation following 48 hour incubation with 10 mg mL−1 HFBL and 10 mg mL−1 LFBL. Cells were stained for γH2AX foci at 1 hour
post γ-radiation to depict initial DNA double-strand break formation and 48 hours post γ-radiation to measure the cells ability to repair. Merged
image: nucleus stained with DAPI (blue), γH2AX foci (green). (D). Bayleaf samples did not induce radio-sensitivity in HT-29 cells but HFBL fractions
prevented repair of γ-radiation-induced DNA double-strand breaks. Shown are the mean and SD from two independent experiments performed in
duplicate; *p < 0.05, ***p < 0.001.
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Tight junctions have been implicated in cell proliferation
and cancer, where claudins and occludins are the major type
of proteins involved. Claudin 2 is down-regulated following
treatment with all three bay leaf samples, particularly the LFBL
(Table 3). Conversely, expression of claudin 1 is increased,
specifically by the LFBL sample. Occludin expression is also
increased, consistent with it known activation by claudin 1,
once again predominantly by the LFBL sample (Table 3).
Increased expression in both claudin 1 and occludin results in
tight junction disassembly. Furthermore, expression of E-cad-
herin (E-CD) is also increased, resulting in adherens junction
disassembly (Fig. 7). Finally the expression of selected impli-
cated genes were validated using immunofluorescence (Fig. 8)
and qPCR analysis (Fig. 9) with similar fold changes of gene
expression to observed, compared to mRNA-Seq analysis.
A substantial number gene families (13) and individual
genes (67) related to management of oxidative stress were sig-
nificantly up or down regulated by bay leaf fraction treatments
(Table 4). Unlike for other gene classes, which responded most
strongly to LFBL and UFBL, oxidative stress response pathways,
except for SOD2, were more strongly influenced by HFBL
(Table 4). Highest diﬀerential gene up-regulation by HFLB
occurred for genes in cytochrome P450, ferritin, glutathione-S-
transferase, heme oxygenase, nuclear factor (erythroid-derived
2) – like 2 and sequestome 1 families. These are all genes
involved in direct management of ROS and electron exchanges
involving oxygen. Conversely, genes diﬀerentially upregulated
by LFBL which were also unregulated by UFBL, included cyto-
chrome P450 (CYP1A1) and SOD2. Activation of these genes by
LFBL and UFBL can account for P450-catalysed oxidation of
LFBL substrates and production of hydrogen peroxide.
Chromatin condensation into chromosomes is an essential
process in both malignant and normal cells and disruption of
this pathway can also account for observed cell death (Fig. 2).
Several proteins involved in this pathway were also aﬀected by
treatment with bay leaf extracts (Table 5). CDK1 phosphory-
lates the BRRN1 gene, therefore a decrease in CDK1 following
treatment with bay leaf also results in a decrease in BRRN1
expression. BRRN1 activates both CAP-H/H2, which was down-
regulated by LFBL but up-regulated by HFBL, and TOP2A, also
involved with chromatin condensation, was down-regulated by
UFBL, HFBL and LFBL. CAP-H/H2 activates condensin, which
was down-regulated by both UFBL and LFBL. Condensin binds
and activates histone H3 which was selectively down-regulated
by HFBL but unaﬀected by UFLB or LFBL. Finally, BRRN1
binds and subsequently activates TOP2A and was down-regu-
lated by UFBL, HLBL and LFBL.
Discussion
In our previous study, unfractionated bay leaf extract
produced anti-proliferative eﬀects on HT-29, SW-480 and
HCT-116 human colon cancer cell lines.26 Furthermore, HFBL
and LFBL were also shown to influence HT-29 cell death by
complimentary apoptotic and glutathione-sensitive eﬀects and
it was proposed that redox-active polyphenol oxidase (PPO)
could account for diﬀerentiated activity of HFBL versus LFBL26
The superior eﬃcacy of HFBL versus LFBL on driving apoptotic
cell death by caspase 3/7-dependent autophagic cell death via
the mitochondria/cytochrome c-mediated activation path-
ways27 was confirmed in the present study (Fig. 1C). However,
Fig. 4 Eﬀects on gene expression in HT-29 cells exposed to bay leaf size fractions for 48 h. Compared with the control, treatment with UFBL (A),
HFBL (B) and LFBL (C) samples results primarily in up-regulation of genes, with fold-changes falling mainly between 0 and 5.
Fig. 5 Majority of up-regulated gene expression changes are common
for all three extracts of bay leaf. Venn diagrams demonstrating the
overlap of changes in either up-regulation (A) and down-regulation (B)
of gene expression for UFBL, HFBL and LFBL samples, compared with
control.
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the demonstration that HFBL, but not LFBL, mediated DNA
strand breaks necessitated the involvement of a toxic species
that could penetrate cellular and nuclear membranes. Cell via-
bility measures indicated that LFBL was more eﬀective than
HFBL and the potency of LFBL increased with incubation time
(Fig. 1A and 1B). However, γH2AX lesions were exclusively
mediated by HFBL, and amplified by γ-radiation, suggesting
that unsuppressed free radical species were responsible for
activity of HFBL. Subsequent gene expression profiles of HT-29
cells revealed that HFBL and LFBL induced diﬀerentiated
adaptive cellular responses including in: cell cycle arrest and
apoptosis, ROS defense and repair of DNA damage.
Table 2 Fold-change showing up-regulation (red) and down-regulation (blue), of genes involved in cell cycle and apoptosis following treatment
with UFBL, HFBL and LFBL bay leaf extracts
Food & Function Paper
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Cell culturing and reactive oxygen species (ROS)
Oxidation of ferrous iron by oxygen under cell culturing
conditions can produce ROS including superoxide, hydrogen
peroxide and hydroxyl radicals.28 Likewise, selected phyto-
chemicals with anti-oxidant properties (pAOX), can promote
production of hydrogen peroxide in cell culture media such as
DMEM containing ferrous iron.29–31 Cellular responses due to
hydrogen peroxide toxicity can account for apparent anti-
proliferative eﬀects of pAOX species29 and explain up-regulation of
similar genes for diﬀerent pAOX species. For example, some of
the p53-dependent apoptosis genes influenced by LFBL in this
study were common to those up-regulated in HT-29 cells by
rosemary extract also cultured in media containing iron.32 We
hypothesize that although LFBL species eﬀectively promoted
ROS-mediated cell damage and apoptosis in the surrounding
media including attacking cell junctions (Table 3), upon
uptake of both ROS and LFBL into cells, LFBL mediated AOX
protection, stimulated AOX cell defences, including upregula-
tion of Cytochrome P450 and SOD2 (Table 4), and prevented
DNA damage. The pattern of ROS/LFBL-mediated apoptosis
of HT-29 cells was relatively delayed compared with HFBL
(Fig. 2).
Conversely, in the presence of HFBL, oxidation of polysac-
charide species by hydroxyl radicals can produce hydroxyl-
alkylperoxyl radicals, which in turn release superoxide,33 and
could feasibly contribute to the iron-mediated ROS in the cell
media. Transmission of ROS through cellular and nuclear
membranes, but not extra-cellular HFBL, produced DNA
damage and a distinct profile of oxidative stress gene
responses compared with LFBL (Table 4). DNA strand breaks
were also shown to be concentration-dependently mediated by
superoxide in the presence of the large glycoprotein ricin.34
Likewise, superoxide-mediated damage to DNA was manifested
as strand breakage, causing base modification and decrease in
melting temperature.35 The gene expression responses associ-
ated with HFBL and LFBL can therefore be interpreted to
reflect distinct ROS-mediated pathways of activity, and eﬀects
of intra-cellular protective eﬀects that suppressed DNA
damage, exerted by LFBL. The comparable pro-apoptotic
eﬀects of extracellular HFBL observed by γ radiation, a positive
control for ROS production, support the interpretation that Fe-
mediated ROS was also involved in HFBL-mediated apoptosis
in cell culture experiments.
Unlike for other pathways (Tables 2 and 3), expression of
genes regulating oxidative stress were mostly upregulated by
HFBL and down regulated by LFBL (Table 4). The exception
was SOD2 which was more strongly upregulated by LFBL versus
HFBL, supporting the previous interpretation. Opposing direc-
tions of fold-changes between HFBL and LFBL, were observed
for cytochrome P450, glutathione peroxidase (HFBL promoted
defense against lipid peroxidation), glutathione-s-transferase
(HFBL promoted glutathione-mediated reactivity with HFBL
substrates). A key specific growth-suppressing bioactivity of
HFBL appears to be the result of strong upregulation of
sequestome 1 (p62) (>20-fold) which mediates autophagy-
dependent tumour suppression through suppression of ROS,
also involving KEAP1 (Table 4).36 LFBL displayed comparatively
lower capacity to stimulate either sequestome 1 or KEAP1,
instead expressing SOD2 (Table 4). Based on the distinct gene
expression profile stimulated by HFBL versus LFBL (Table 4), it
seems that ROS defense associated with LFBL were mediated
by SOD2 and by sequestome 1 and KEAP1 for HFBL.
Eﬀects on apoptosis
The intrinsic pathway of cell death was initiated following
treatment of HT-29 cells with bay leaf, whereby similar levels
of increased fold-change for caspase and other cell death-regu-
lating genes was evident for either UFBL, HFBL or LFBL
(Table 2). Cell death involves multiple proteins, beginning
with release of cytochrome c from the inter-membrane space
of the mitochondria into the cytoplasm. The release of such
proteins is a result of increased Bim expression (elevated
equally by UFBL, HFBL or LFBL), which directly mediates Bak
and Bax (also increased expression post-treatment with bay
leaf ), leading to the cytochrome c release. Cytochrome c then
binds to apaf-1 protein, in turn causing its activation. Apaf-1
subsequently binds ATP/dATP forming the apoptosome and
mediating activation of caspase 9. This initiates the caspase
cascade, leading to the activation of subsequent caspases,
including caspase-3 and caspase-7, both up-regulated by bay
leaf. Bax plays a pivotal role in inducing apoptosis by control-
ling the release of the IAP-binding mitochondrial protein,
Smac/Diablo from the mitochondria. Smac/Diablo binds to the
IAP protein, survivin, subsequently inhibiting it. Survivin
expression is decreased by bay leaf extract, and leads to
increased expression of cytochrome c, (Table 2). While the
caspase 3/7 assay showed a significantly increased level of cell
death post-treatment with the HFBL, this was not replicated in
the gene expression levels determined by mRNA-Seq. The high
dynamics and post-translational modifications of proteins can
influence protein detectability, and may explain the diﬀerences
observed in gene expression from RNA-Seq studies as com-
pared to results obtained in the laboratory.37 Specifically,
while mRNA expressions may remain constant between the
cells treated with the three diﬀerent bay leaf samples, the indi-
Table 3 Pre-treatment with bay leaf causes up- (red) and down-regu-
lation (blue) of genes involved with both adherin and tight junctions,
inﬂuencing cell invasiveness and subsequently metastasis. Bay leaf has
opposing eﬀects on claudin-1 and -2 causing up- and down-regulation
respectively, thereby aﬀecting the adhesion of tight junctions within
cells
Paper Food & Function
2514 | Food Funct., 2015, 6, 2507–2524 This journal is © The Royal Society of Chemistry 2015
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Table 4 Pre-treatment with bay leaf causes up- (red) and down-regulation (blue) of genes involved with defense against oxidative stress
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vidual fractions may stimulate post-translational events of
genes that will in turn aﬀect their activation and subsequent
action. Nevertheless, the increased expression of proteins
driving intrinsic cell death, including by HFBL, together with
the caspase 3/7 assay results, support the primary role of HFBL
in initiation of cell death in HT-29 cells.
Diﬀerential eﬀects on DNA damage and repair by HFBL
and LFBL
An early cellular response to DNA double-strand breaks (DSBs)
is the phosphorylation of H2AX, a minor histone H2A
variant.38,39 The rapid phosporylation of H2AX at the Ser-139
C-terminus to produce γH2AX can be measured as a biomarker
of DNA damage and repair.40,41 DSBs are the most critical cell
lesion with respect cell survival as they aﬀect the linear conti-
nuity of the genome38 and can be produced by ionizing radi-
ation.40 Following 48 hour incubation with HT-29 cells, bay
leaf samples produced significant numbers of γH2AX foci,
with highest eﬀect by HFBL (>25 foci per cell) compared with
UFBL and LFBL (both <15 foci per cell, Fig. 3). Eﬀects of HFBL
on the yield of DNA DSBs demonstrate the distinct nature of
the cytotoxic lesion by HFBL alone, and not by LFBL, which
was further amplified by ionizing radiation.
CBX4 is an early DNA damage response protein that stimu-
lates the accumulation of BMI1 at DNA damage sites.42,43 Fur-
thermore, the removal of CBX4 results in decreased cellular
Fig. 6 The expression of a number of genes involved in apoptosis and cell cycle regulation are aﬀected by treatment with bay leaf extracts. Tumor
suppressor p53 is primarily up-regulated by HFBL, which inﬂuences a number of genes involved in p53-dependent cell death, DNA repair, and
initiation of cell cycle arrest.
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Fig. 7 Treatment with bay leaf disrupts genes involved in both tight and adherin junctions, ultimately resulting in their disassembly. Post-treatment
with bay leaf, a decrease in expression of Wnt, and simultaneous increase in expression of ID2, Axin 2, APC, β-catenin and E-cadherin is observed.
Similarly, an increase of tight junction proteins claudin-1 and occludin is seen, while a decrease in claudin-2 is noticed.
Fig. 8 Validation of mRNA-Seq data was also employed by immunoﬂuorescence assays. HT-29 cells pre-treated with HFBL and LFBL fractions were
ﬁxed and stained for anti-claudin-2 (red) and anti-HDAC8 (green). Shown are representative photomicrographs of HT-29 cells treated with HFBL or
LFBL samples; bar = 50 µm (A). The mean ± SD of the total ﬂuorescence intensity of claudin-2 (B) and HDAC8 (D) in a single cell are shown. Similar
trends were observed in mRNA expression fold changes for genes claudin-2 (C) and HDAC8 (E).
Food & Function Paper
This journal is © The Royal Society of Chemistry 2015 Food Funct., 2015, 6, 2507–2524 | 2517
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
resistance to ionizing radiation.42 Following treatment with
UFBL, HFBL and LFBL, CBX4 gene expression was increased
by 22.4, 15.3 and 28.1 fold change, respectively, suggesting
that bay leaf samples would be diﬀerentially protective against
ionizing radiation, with highest protection aﬀorded by LFBL
followed by UFBL. In addition, BMI1 was also increased 2.2, 0
and 4 fold for UFBL, HFBL and LFBL respectively (data not
shown) which was validated by qPCR (Fig. 9). This can explain
the lack of repair of HFBL-mediated DNA damage and signifi-
cantly elevated γH2AX foci evident at 48 hours post irradiation
(Fig. 3D).
Following DNA damage, cells undergo a series of complex
processes including cell cycle arrest, activation of genes
involved in repair of DNA, and in extreme cases the initiation
of programmed cell death.44 In the case of malignant cells
increasing their repair capacity, promotion of cellular resist-
ance to the DNA-damaging agent will follow. As such, the
genes and proteins involved with DNA repair may promote
disease resistance to therapy. The Rad51 recombinase, a key
player in eukaryotic DNA double-strand break repair, is
an essential factor involved in homologous recombination
repair.45,46 Tumor cells have increased levels of Rad5144,47
which results in increased resistance to DNA damage by
chemotherapeutic drugs, which in turn, permits tumor pro-
gression, and may contribute to genomic instability.46 Relative
to control, Rad51 expression was increased by HFBL (+1.26
fold), but decreased by LFBL (−2.1-fold, Table 2). In addition,
PCNA augments DNA polymerase activity resulting in DNA
replication and modulation of DNA repair processes including
mismatch repair.48–50 As for Rad51, LFBL was also associated
with a decrease in expression of PCNA, thus contributing to
inhibition of repair of HFBL ROS-mediated DNA damage.
Diﬀerential responses of chromatin condensation genes, con-
densin and CAP-H/H2 (Table 5), favoring their upregulation by
HFBL but down-regualtion by LFBL, further supported that
diﬀerent apoptotic pathways were mediated by respective
fractions.
Eﬀects on cell cycle
Bay leaf extracts delayed cell cycling, reduced viability and
increased apoptosis (as measured by caspase 3/7 assays, Fig. 1)
and necrosis in cultured HT-29 cells. This is reflected in the
increased proportions of bay leaf-treated cells in sub G1 phase,
with the eﬀects of HFBL being observed early (24 h) while the
eﬀects of LFBL were more delayed. (Fig. 2). The relative
increase in the proportion of cells in S phase after 24 h
suggested that both HFBL and LFBL elicited cell cycle arrest
somewhere in the transition from G1 to S phase (Fig. 2).
CDKs are a conserved family of protein kinases that control
orderly progression through phases of the cell cycle, regulate
the rate of proliferation and therefore represent promising
targets for anti-cancer therapy.51,52 CDKs associate with
Fig. 9 Trends in gene expression changes measured by qPCR were in agreement with those measured by mRNA-Seq. HT-29 cells were treated
with UFBL, HFBL and LFBL samples prior to isolation of the RNA. The RNA of selected genes shown was ampliﬁed by RT-PCR and the results are
expressed as the fold change in mRNA expression from the untreated cells.
Table 5 Pre-treatment with bay leaf causes up- (red) and down-regu-
lation (blue) of genes involved with chromatin condensation
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various cyclin regulatory subunits, forming cyclin-CDK
complexes which are critical regulators of cell-cycle progression
in both malignant and normal cells.53 NGS analysis revealed
altered expression of the CDKs by treatment with all bay leaf
samples (Table 2). LFBL aﬀected expression of a number of
genes involved in the cell cycle progression by cyclin/CDK
complex, and LFBL but not UFBL or HFBL, down-regulated
CDK2 (Table 2). CDK2 associates with, and is regulated by
both the regulatory cyclins E and A, both of which were
also down-regulated by LFBL. While the CDK2/cyclin
A complex is necessary for progression through the S phase
of the cell cycle and studies have demonstrated that degra-
dation of both CDK2 and cyclin A together causes massive
tumor cell apoptosis both in vitro and in vivo,51 cyclin E is a
requisite regulator of the G1–S transition. Cyclin E is often
over-expressed in human malignancies, and supports the
notion that deregulation of cyclin E/CDK2 may contribute to
carcinogenesis.54
Specifically, p53 activates p21 leading to its subsequent
increase, and mediation of p53-dependent growth arrest. CDK
inhibitors (Cip/Kip) are well characterized for their role as
negative regulators of cell cycle progression through inter-
action and subsequent inhibition of CDK molecules.55 In par-
ticular, p21cip1 and p27kip1 inhibit a broad-spectrum of cyclin-
CDK complexes, including the cyclin A/CDK2 complex, and
cyclin E/CDK2 complex. P21 is a cell cycle inhibitor, playing a
significant role in halting cellular proliferation and having the
ability to promote diﬀerentiation and cellular senescence via
the formation of a quaternary complex with cyclins, CDKs and
PCNA.56,57 P21 mediates its various biological activities mainly
by inhibiting the kinase activity of the CDK1 and CDK2,
leading to cell cycle arrest at specific stages. In the present
study, levels of p21 were up-regulated following treatment with
all three bay leaf samples, and a significant increase in p27
expression was also observed after treatment of cells with
LFBL, but not UFBL or HFBL. Up-regulation of p21 is signifi-
cant as ineﬃcient expression of this gene equates to decreased
survival rates in patients with CRC.58,59 Additionally, as CDK2
blocks p21 expression, the decreased levels of CDK2 lead to an
up-regulation of p21. In this light, the suppression of cell pro-
liferation and the cell cycle arrest at either the G1 or S phases
induced by LFBL (i.e., peroxide) treatment most likely results
from its ability to decrease expression of CDK2, cyclin A and
cyclin E.
Alternatively, if DNA damage is severe, p53 promotes apop-
tosis. Activating transcription factor 3 (ATF3) is part of the
ATF/CREB family of bZIP transcription factors, and is charac-
terized as a stress-inducible or adaptive response gene.60,61
Eﬀects of LFBL on cell cycle and apoptosis can also be
accounted for by the significant up-regulation of ATF3 (214.3
fold, Table 2). ATF3 is described as a regulator of tumor sup-
pressor functions in colorectal carcinogenesis62 that most
likely stabilizes and increases transcriptional activity of p53 in
the genotoxic response.63 Further, over-expression of ATF3 pro-
motes induction of cell cycle arrest and inhibition of prolifer-
ation, through antagonising the expression of cyclin A,64
induction of apoptosis, and an overall retardation of tumor
formation.65
Eﬀects on tumor suppression
Previously described as the ‘guardian of the genome’,66 the
development of more than 50% of human cancers is associ-
ated with the loss of, or mutations in the p53 gene,67 which
can also cause resistance of therapy.68 By regulating an array of
genes, p53 exerts its tumor suppressor eﬀect as a molecular
switch, inducing death of cells with irreversibly damaged DNA
or other genomic errors.68,69 Over 75% of colorectal carci-
nomas involve a deletion at 17q, which is thought to aﬀect the
tumor suppressor gene, p53.70 Following DNA damage, p53
delays the G1 phase to permit DNA repair.
71,72 All bay leaf
samples caused up-regulation of p53 expression that can
account for HT-29 growth arrest. However, p53 expression at
48 h was higher for LFBL than HFBL (Table 2) whereas apop-
tosis was more extensive for HFBL (Fig. 2), suggesting that
DNA damage caused by HFBL was diﬀerent and not assisted
by this repair pathway to the same extent as LFBL.
In addition to the p53 pathway, phosphatase and tensin
homolog protein (PTEN) is a potent tumor suppressor gene
that is also often mutated in human cancers.73 PTEN auto-
regulates its expression through stabilization of p53, and has
been shown to enhance p53 transactivation.74 Further, this
gene down regulates the activity of the lipid second messenger
phosphoinositol-3,4,5-triphosphate (PIP3) through dephos-
phorylation, thereby negatively regulating PIP3K-triggered sig-
naling. The PI3 K/Akt pathway is an important driver of cell
proliferation and survival. Through the negative regulation of
this signaling pathway, PTEN modulates cell growth and survi-
val causing a decrease in cell migration and invasion and
additionally resulting in cell cycle inhibition.75,76 In this
regard, PTEN is frequently deleted in advanced tumors,
however post-treatment with HFBL, an increase in expression
of this transcript was observed.
ATF3 and PTEN are among many known proteins that inter-
act with p53.69 Following treatment with the HFBL, the
expression of another p53-target gene, oxidative stress-induced
growth inhibitor 1 (OSGIN1), was significantly increased
(Table 2). OSGIN1 is ubiquitously expressed and a putative p53
binding site has been located at the OSGIN1 promoter, indicat-
ing that this gene is regulated by DNA damage in a p53-depen-
dent manner.77 OSGIN1 regulates the diﬀerentiation and
proliferation of cells, and its over-expression induces apoptosis
and cell death, as shown in A498 (malignant kidney cells),
buﬀalo rat liver, and MCF-7 (malignant breast cells).78–80 Loss
of OSGIN1 is positively correlated with rapid tumor growth
and metastasis.81 Conversely, its upregulation by bay leaf, par-
ticularly by LFBL (Table 2), likely contributed to induction of
HT-29 apoptosis and cell death.
Another protein that also contains a p53-promoter region is
the VH1-like enzyme, dual specificity protein 5 (DUSP5).
Binding of p53 to the promoter region of DUSP5 has been
shown to activate this gene in response to DNA damage in
colon-cancer cells.82 Further, growth suppression in four dis-
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tinct cancer cell lines was associated with elevation of DUSP5
expression, which may involve phosphatase activity toward
mitogen-activated protein kinases, including MAPK3. As for
OSGIN1, LFBL significantly up-regulated expression (∼271-
fold), more eﬀectively than either UFBL (∼1.6-fold) or HFBL
(∼3-fold), and may also contribute to the growth-suppressing
eﬀects of bay leaf on HT-29 cells. Up-regulation of OSGIN1 and
DUSP1 by a solvent extract of rosemary, likely enriched in low
mass polyphenolics and under potential ROS-producing con-
ditions, was recently reported.32
Eﬀects on cell membrane integrity and tumor metastasis
Tight junctions are essential for the sealing of the cellular
sheets, therefore controlling paracellular ion flux and main-
taining tissue homeostasis. Tight junctions also play a crucial
role in the maintenance of cell polarity by forming a barrier
that acts to prevent lateral diﬀusion of membrane proteins and
lipids, thereby maintaining the diﬀerential composition of the
apical and basolateral domains. Tight junctions are composed
of three major integral membrane proteins, occludins, claudins,
and junctional adhesion molecules (JAMs). Loss of cellular
organization due to impairment of apical and tight junctions
has been implicated in cell proliferation and cancer.83 Silencing
of occludin promotes cancer cell tumorigenesis and metasta-
sis.84,85 Compared with other fractions, LFBL was associated
with stronger increased expression of occludin (Table 3), also
favouring more eﬀective suppression of HT-29 proliferation.
While decreased claudin expression is observed in a
number of human malignancies, leading to compromised
tight junction function, this does not seem to be the case for
claudin-2, where high expression levels were seen in CRC.86
Treatment with the bay leaf, particularly LFBL, significantly
decreased expression of the tight junction protein, claudin-2
Table 3). Claudin-2 is a unique member of the claudin family
of transmembrane proteins, and its role in neoplastic trans-
formation and growth was confirmed by up-regulation and
correlation with cancer progression in tissues from 309 CRC
patients.86 Moreover, expression of claudin-2 in breast cancer
was correlated with liver metastasis.87 These data suggest that
claudin-2 plays a role in cancer cell metastasis, possibly in the
specific invasion of the liver, which is the most common site of
metastasis and cause of death in CRC.48,88 It has been pro-
posed that up-regulation or aberrant tissue expression of
certain claudins may contribute to neoplasia by directly altering
tight junction structure and function, and also by aﬀecting cell
signalling pathways.86 Eﬀects of bay leaf treatment (both HFBL
and LFBL, Table 3) on down-regulation of claudin-2 protein
synthesis was confirmed by immunofluorescence (Fig. 7) sup-
porting the potential for claudin-2-mediated tumor suppressing
eﬃcacy of bay leaf, particularly LFBL (−50.7-fold, Table 3), and
another potentially protective pathway of CRC pathogenesis.
In contrast to the decreased expression of claudin-2, all bay
leaf samples, particularly LFBL, increased expression of
claudin-1 (Table 3). Claudin-1 expression is often down-regu-
lated in human malignancies, thus an increase of this gene via
treatment with LFBL oﬀers a potential mechanism of action.
When the integrity of the tight junction is lost, there are many
events that may contribute towards the promotion of tumori-
genesis. The ability for nutrients to diﬀuse into malignant
cells encouraging cell growth and survival,89 decreased polarity
and diﬀerentiation may influence the potential for meta-
stasis90 and finally, the unrestrained growth of the cell all
contribute to rapidly proliferating and cells.91
In addition to the claudins, calcium-dependent cell–cell
adhesion transmembrane glycoprotein’s (cadherins, E-CD),
mediate homophilic adhesion between cells and are also
linked with cancer metastasis.92,93 Treatment with bay leaf
fractions increased expression of E-CD with higher fold-change
for LFBL (+6.2-fold) and UFBL (+3.9-fold) versus HFBL (+2.0-
fold, Table 3). In contrast, E-CD is typically under-expressed in
cancer cell lines and down-regulation of E-CD in human carci-
nomas correlates positively with malignant cell invasion.94 Pro-
motion of E-CD by LFBL and consequent suppression of
cancer cell invasion94–96 might also be expected to protect
against liver metastasis in CRC.97 Collectively, the significantly
divergent eﬀects of HFBL versus LFBL on cell membrane also
support distinct bioactive species were responsible and that
LFBL-associated hydrogen peroxide was particularly eﬀective
in undermining membrane integrity.
Experimental
Processing and size-fractionation of bay leaf
Dried bay leaf (Laurus nobilis, Hoyts Food Industries, Pty Ltd,
Moorabbin, Victoria, Australia) was obtained from a local
supermarket. Bay leaf was processed to maximize water solubi-
lity of components by dispersing in water, blending in a food
processor, microwave heating, ultrasonicating and freeze
drying (‘Stage 1’ product), as described previously.26 Briefly,
‘Stage 1’ bay leaf product was dispersed at 10% solids (w/w)
with sonication (10 min, Unisonics Pty Ltd, Brookvale, New
South Wales, Australia) before centrifuging (10 000g, 10 min at
20 °C, Model J2-MC, rotor JA-14, Beckmann Coulter Inc., Brea,
CA, USA). The Stage 1 product was the same as that used and
characterised in ref. 26 but it was the Stage 1 and not the Stage
2 product that was fractionated and used in the current study.
Previously, the supernatant was fractionated using preparative
gel filtration chromatography (PD-10 column, Amersham Bio-
sciences, GE Healthcare, Uppsala, Sweden) with 6 successive
1.75 ml aliquots of water and finally 3.5 ml of methanol (frac-
tion 7), under gravity-based elution. For the current study, bay
leaf Stage 1 product supernatant fractions studied were:
unfractionated (UFBL); high molecular mass fraction (HFBL,
PD-10 fractions 1–3, ∼4–18 kDa) and low molecular mass frac-
tion (LFBL, PD-10 fractions 4–7, <1.4 kDa) of Stage 1 bay leaf.
Yields of HFBL and LFBL were 3.1% and 3.6% (w/w) of total
Stage 1 product solids. The compositional characteristics of
the original series of products using HPLC, LCMS and
SDS-PAGE methods were described previously.26 Dried UFBL,
HFBL or LFBL were prepared in 10% ethanol (v/v) at 1 g ml−1,
filter sterilised (0.22 µm) and stored at −80 °C until use.
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Cell culture
HT-29 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% (v/v)
FBS, 1 mM sodium pyruvate and 1% antibiotic-antimycotic.
Cells were grown as monolayers in a humidified 5% CO2
environment at 37 °C. Single cell suspensions were prepared
by trypsinization (0.05% (v/v) trypsin/EDTA solution (Invitro-
gen, Carlsbad, CA, USA) for 10 minutes at 37 °C, as required.
For maintenance, cells were passaged once per week and
seeded at ratios 1 : 10.
Cell viability and apoptosis
Cells were seeded at a density of 15 000 cells per well in black,
flat bottom, 96-well plates (Nalge Nunc, Penfield, NY, USA) and
allowed to attach overnight. Bay leaf samples were diluted in
culture medium to the required concentrations and incubated
at 37 °C, 5% CO2. Cell viability was determined after 24 and
48 hours exposure to the bayleaf extracts and measured using
the Cell-Titer Blue® Assay kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Cell-Titer Blue
reagent was added to each well and incubated for 4 hours at
37 °C, 5% CO2, before reading fluorescence intensity (550 nm
excitation; 615 nm emission) using the Perkin Elmer Victor3
(Perkin Elmer, MA, USA) multi-label plate reader. Apoptosis was
measured by the level of Caspase 3/7 activity following 48 hours
exposure to the bay leaf extracts, using the Apo-ONE Homo-
geneous Caspase 3/7 assay kit (Promega, NY, USA) according to
the manufacturer’s instructions. Fluorescence intensity (485 nm
excitation; 525 nm emission) was measured using the Perkin
Elmer Victor3 multi-label plate reader 4 hours following incu-
bation with Apo-ONE reagent at 22 °C, on a rotating platform.
Flow cytometric analysis
Flow cytometry was utilized for cell cycle analysis. HT-29 cells
were treated 20 mg ml−1 of UFBL and 10 mg ml−1 of HFBL and
LFMBL fractions for 24 and 48 hours before they were har-
vested with 0.05% trypsin and washed with ice-cold PBS con-
taining 2% (v/v) FBS twice and fixed overnight with continuous
rotation in 70% (v/v) ethanol at 4 °C. Cells where then stained
in 100 µg mL−1 propidium iodide containing 1 µg mL−1 RNase
A (Qiagen Inc., Valencia, CA), overnight whilst on rotation at
4 °C. Samples were then transferred to FACS tubes and ana-
lyzed by flow cytometry using a Facs Calibur cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). Fluorescent debris was
gated using forward scatter versus orthogonal side scatter with
a secondary gate placed around the single cell population
using a pulse area versus plate width dot plot. The percentage
of cells in each phase of the cell cycle was analyzed using Cell
Quest software (version 5.1, BD Biosciences, San Jose, CA, USA).
γH2AX immunofluorescence
HT-29 cells were seeded at 15 000 cells per well in 8-well
chamber slides (Lab-tek, Nunc, New York, USA) and allowed to
attached overnight. Cells were then treated with 20 mg mL−1
crude extract, 10 mg mL−1 HFBL and 10 mg mL−1 LFBL frac-
tions for 48 hours, at 37 °C, 5% CO2, prior to γ-radiation
(137Cs) at 0 or 4 Gy, and incubated for a further hour at 37 °C,
5% CO2. Cells were then stained and quantified for the
number of γH2AX foci per cell nuclei as previously described.39
All analysis was performed using image analysis freeware (FIJI
Image J, version 1.46d). A minimum of 2 independent experi-
ments were completed in duplicate and results are expressed
as the mean ± standard deviation.
Library construction, mRNA sequencing and pathway analysis
Total RNA was isolated from cells pre-treated with either
control (10% ethanol), UFBL (20 mg ml−1) or HFBL and LFBL
(both 10 mg ml−1) for 48 hours using Trizol (Invitrogen), fol-
lowing manufacturer instructions. RNA extraction, library
preparation, alignment to the genome and bioinformatics ana-
lysis to obtain fold changes in mRNA expression was per-
formed as previously described.98 The online program
MetaCore (GeneGo Inc. St. Joseph, MI, USA) was used for
pathway analysis. A fold-change of >1.5 was considered statisti-
cally significant.
qPCR validation of next generation gene sequencing data
Total RNA was purified from control and treated cells using
TRIZOL following manufacturer instructions. RNA was quan-
tified with a Nanodrop spectrophotometer (Thermo Fisher)
and Qubit fluorometer (Life Technologies). The integrity of
the RNA was assessed using a MultiNA Microchip Electro-
phoresis System (Shimadzu, Kyoto, Japan). High-capacity
cDNA reverse transcription kit from Applied Biosystems (P/N
4375222) was used to reverse transcribe RNA following the
manufacturer instructions. qPCR reactions were performed
using Sybr fast (Roche, Penzberg, Germany) on cDNA
prepared from RNA. Certain oligonucleotides were designed
using Primer blast online tool on published sequences
for human RNA (NCBI, Drumcondra, Dublin). Primers
were synthesized by Geneworks (Gene Works Pty Ltd, Hind-
marsh, SA, AUS): CBX4 5′-GGTGGTCGGGCCTTTTGAGCT-
3′ and 5′-GCGCCCGGCCTCAGAGTTCTA-3′; NFKBIE
5′-ACCCACTGCAACTTGGAAAGGCA-3′ and 5′-GGCCCTGCT-
AGGTCACCCCT-3′; HIST4H4 5′-GTCTTGCGCTTGGCGTGCTC-3′
and 5′-ACGAGGAGACCCGGGGAGTC-3′; GPSM3 5′-CAGGTGG-
AGGCCTGAGCCCT-3′ and 5′-GGGGGATCCCAGGCACCCAT-3′
(Sigma-Aldrich, St Louis, MI, USA). PCR was performed on ABI
Fast 7500 (Applied Biosystems, Carlsbad, CA, USA). The house-
keeping gene used as an endogenous control for the experi-
ment was β-actin. Key genes were validated by RT-PCR and
immunofluorescence.
Immunofluorescence staining
Immunofluorescence staining was employed for validation of
gene expression changes as seen by mRNAseq analysis using
expression of proteins: claudin-2 and HDAC8. HT-29 cells were
seeded at 40 000 cell per well in glass LabTek™ II 8-well
chamber slides (Thermo scientific, Rochester, NY, USA) and
allowed to attach overnight prior to 48 hour incubation with
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UFBL, HFBL and LFBL samples at a concentration of 10 mg
ml−1. The cells were washed twice with PBS for one min on
rotation and fixed with 4% PFA (Sigma-Aldrich) for 10 min at
22 °C. Following a brief wash with PBS, the cells were permea-
bilized using 0.1% Triton X-100 (Sigma-Aldrich) for 10 min at
22 °C, washed three times with PBS and blocked with 1%
bovine serum albumin (BSA, Sigma-Aldrich) whilst on rotation.
Cells were then incubated with rabbit monoclonal anti-
claudin-2 (Epitomics, Burlingame, CA) and mouse monoclonal
anti-HDAC8 (Sigma-Aldrich) primary antibodies diluted in 1%
BSA (1 : 100; Sigma-Aldrich) for one hour at 22 °C in a humid
chamber. Following three consecutive washes in PBS, cells
were incubated with a secondary goat anti-rabbit antibody
(1 : 100 in 1% BSA) conjugated with Alexa-546 (Molecular
Probes, Oregon, USA) and goat anti- mouse antibody (1 : 100 in
1% BSA) conjugated with Alexa-488 (Molecular Probes) incu-
bated for one hour in a dark humidified environment on a
rotating platform at 22 °C. Following three consecutive washes,
cells were mounted with prolong Gold anti-fade solution with
DAPI (Molecular Probes), cover-slipped (Biolab, VIC, Australia)
and sealed with nail polish. Images were acquired using an
Olympus BX61 motorised upright fluorescence microscope
automated with FVII Camera using a 40× Uplan FL oil objec-
tive with fluorescence filter cubes: DAPI (Ex: 350/50, Em: 460/
50 nm) and FITC (Ex: 470/40, Em: 525/50 nm). Fluorescence
intensity of each protein was analyzed using image analysis
freeware FIJI Image J (version 1.46d, Image J software).
Statistical analysis
A minimum of 2 independent experiments were completed for
cell-based assays. Results are expressed as the mean ± standard
deviation (SD). Statistical analysis was performed using a Stu-
dent’s t-test in GraphPad Prism (version 5, GraphPad Software
Inc, CA, USA), and results for significances P, designated by *P
< 0.05, **P < 0.01, ***P < 0.001.
Conclusion
We propose that HFBL and LFBL extracts each promoted
HT-29 apoptosis by mechanisms involving ROS. The pro-apop-
totic eﬀects of Fe-mediated ROS production bay leaf fractions
in cell culturing conditions were capitulated by ionizing radi-
ation-mediated ROS production, supporting that bay leaf frac-
tions modulated cellular responses involving ROS. Diﬀerent
mechanisms of apoptosis are inferred from diﬀerent rates of
apoptosis, gene responses and DNA-specific damage associ-
ated with LFBL versus HFBL. Patterns of gene expression
reported for HT-29 challenge by rosemary extract, also cultured
in DMEM containing ferrous iron,32 were comparable to that
reported for LFBL, supporting a common mechanism. Simi-
larly, the pattern of HFBL toxicity was comparable to super-
oxide-mediated toxicity observed in the presence of the
glycoprotein ricin.34 Gene expression analysis provided a
comprehensive mechanistic framework for understanding the
distinct eﬀects of HFBL versus LFBL on modulating ROS-
mediated toxicity.
HFBL-mediated ROS production initiated more rapid apop-
tosis by non-repairable DNA DSBs. In comparison, LFBL pro-
moted extra-cellular toxicity of ROS but protected against DNA
damage. LFBL promoted selective stimulation of genes driving
G1 cell cycle arrest, failure of cell assembly at tight junctions
and inducing p53-dependent apoptosis and attenuated cellular
recovery by suppressing DNA repair. These distinct biological
eﬀects were not apparent for UFBL, and gene expression pat-
terns associated with UFBL were more similar to LFBL than
HFBL. HFBL-mediated ROS defense was associated with
changes in cytochrome P450 (CYP3A5 and others), glutathione
peroxidase, glutathione-s-transferase, heme oxygenase and
sequestome 1 whereas LFBL-mediated ROS defense involved
cytochrome P450 (CYP1A1 and others) and SOD2. This study
oﬀers information about signatures of gene expression to
identify if ROS-mediated or direct eﬀects are causing cell
death, particularly to inform interpretation of eﬀects of other
phytochemical extracts.
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